within Pharmacolibrary.Drugs.ATC.J;

model J05AF09
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.93,
    Cl             = 25.3 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,
    adminCount     = 1,
    Vd             = 0.00123,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.018333333333333333,
    Tlag           = 9.96
  );

  annotation(Documentation(
    info ="<html><body><p>Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) used as an antiretroviral drug in the treatment and prevention of HIV-1 infection. It is often used in combination with other antiretrovirals and is approved for clinical use worldwide.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult individuals after oral administration of 200 mg emtricitabine.</p><h4>References</h4><ol><li><p>Fonsart, J, et al., &amp; Molina, JM (2017). Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial. <i>The Journal of antimicrobial chemotherapy</i> 72(2) 478–485. DOI:<a href=&quot;https://doi.org/10.1093/jac/dkw412&quot;>10.1093/jac/dkw412</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28073964/&quot;>https://pubmed.ncbi.nlm.nih.gov/28073964</a></p></li><li><p>Thurman, AR, et al., &amp; Doncel, GF (2021). Safety and Pharmacokinetics of a Tenofovir Alafenamide Fumarate-Emtricitabine based Oral Antiretroviral Regimen for Prevention of HIV Acquisition in Women: A Randomized Controlled Trial. <i>EClinicalMedicine</i> 36 100893–None. DOI:<a href=&quot;https://doi.org/10.1016/j.eclinm.2021.100893&quot;>10.1016/j.eclinm.2021.100893</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34041459/&quot;>https://pubmed.ncbi.nlm.nih.gov/34041459</a></p></li><li><p>Dando, TM, &amp; Wagstaff, AJ (2004). Emtricitabine/tenofovir disoproxil fumarate. <i>Drugs</i> 64(18) 2075–2084. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200464180-00005&quot;>10.2165/00003495-200464180-00005</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15341498/&quot;>https://pubmed.ncbi.nlm.nih.gov/15341498</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J05AF09;
